Keywordslipidomics; omega 3 fatty acids; lipid analysis; lipidome; cardiovascular disease; clinical trials; pig; pork; n-3; omega-3; LNA; ETA; EPA; DHA; n-3 fatty acids; subcutaneous; adipose tissue; marine; breast cancer; lysophosphatidic acid; epidermal growth factor; ω-3 fatty acids; G protein-coupled receptors; free fatty acid receptors; fatty acids (FAs); n-3 polyunsaturated fatty acids (PUFAs); docosahexaenoic acid (DHA); eicosapentaenoic acid (EPA); apoptosis; cytotoxicity; cancer therapy; combinational therapy; drug resistance; cancer stem cells; α-linolenic acid (ALA); cardiac muscle; lipotoxicity; dyslipidemia; insulin resistance; high-sucrose diet; C. elegans; polyunsaturated fatty acids; fat-1; omega-3 desaturase; skin cancer; omega-3 fatty acids; ultraviolet radiation; prostaglandins; immune modulation; long chain omega-3 polyunsaturated fatty acid; cancer; single nucleotide polymorphism; eicosanoids; genotype; fish oil; preconditioning; antioxidant; reactive oxygen species; ischaemia; reperfusion; n-3 PUFA; lipid oxidation; infarct; parenteral nutrition; omega-3 fatty acids; omega-3 PUFA; lipid emulsions; alpha linolenic acid; maternal diet; fetal programming; metabolic syndrome; gene expression; ω3 fatty acids; polyunsaturated fatty acids; omega-3 fatty acids; mood disorders; schizophrenia; borderline personality disorder; attention deficit hyperactivity disorder; eating disorders; substance use disorder; tolerability; n/a
